|From: NetworkNewsWire (Rep: 0)||Date: 05/14/2018 16:58|
|Forum: Penny Stocks - Msg #1616 - List LXRP msgs ||Thread #674009157 (Rec: 0) |
|NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Awaiting Patent for Promising DehydraTECH Transdermal CBD Application|
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) continues to add numerous U.S. and Australian patents to its existing portfolio. Among these is the company’s recent filing for a new transdermal application of cannabidiol (CBD) that followed successful laboratory evaluation of DehydraTECH delivery results. An article discussing the company reads: “LXRP is a British Columbia-based, cannabis-focused food bioscience company, and it is a technology disrupter for edible cannabinoids. Its DehydraTECH technology aids in the body’s absorption of cannabinoids. … The company’s most recent patent filing follows successful laboratory evaluation of DehydraTECH in the transdermal delivery of cannabidiol (CBD). Results showed an increase of up to 225 percent in permeability when compared to control formulations from leading commercial penetration enhancers. The company indicates that it will begin third-party licensing discussions for this new transdermal application as soon as possible, and, based upon past experience, it expects the patent to be formalized within 100 days.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.